Gossamer Bio, Inc. (GOSS): Insider Trading, Congress Trades & Research | Tormere

GOSS

$9.95+7.22%visit website

Gossamer Bio, Inc.

Market Cap

$4.9B

Live price × SEC shares (Aug 8, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.26

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

91.3

TTM to Jun 2026 · revenue

Flagged input, hover for details

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	13,294	13,799	16,955	9,238	53,286
Research & development	45,542	48,935	43,075	26,412	163,964
Total operating expenses	62,408	59,838	61,821	35,312	219,379
Operating income	(49,114)	(46,039)	(44,866)	(26,074)	(166,093)
Interest expense	2,748	2,751	2,755	2,705	10,959
Pretax income	(48,221)	(47,326)
Income tax	0.0	(88.0)
Net income	(48,221)	(47,238)	(46,664)	16,900	(125,223)
EPS (basic) ($)	(0.21)		(0.20)	0.05	(0.53)
EPS (diluted) ($)	(0.21)		(0.20)	(0.08)	(0.66)
Weighted avg. shares (basic)	227,981		234,137	320,014
Weighted avg. shares (diluted)	227,981		234,137	328,776

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 30 more quarters, back to Mar 2018, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

D. E. SHAW & CO, L.P. · 2026-10-29

No Form 4 transactions on record.

Recent News

Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Yahoo · 2026-10-17

Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Benzinga · 2026-10-13

Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls

Yahoo · 2026-10-13

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Yahoo Finance · 2026-10-01

At Gossamer Bio (GOSS), director Daniel Thomas O's options carry a $10.99 exercise price.

Stock Titan · 2026-09-25

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Yahoo Finance · 2026-09-23

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Yahoo Finance · 2026-09-11

Gossamer Bio plans to cut its share limit from 4 billion to 50 million

Stock Titan · 2026-09-09

Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio

Yahoo Finance · 2026-09-08

Gossamer Bio to Present at Cantor Global Healthcare Conference

Yahoo Finance · 2026-09-04

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Yahoo Finance · 2026-08-27

Gossamer Bio announces $250m in funding to advance seralutinib

Yahoo Finance · 2026-08-24

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Yahoo Finance · 2026-08-16

Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes

Yahoo Finance · 2026-07-02

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?

Stocktwits · 2026-03-05

Informational purposes only, not investment advice.